Recent Articles2022-03-14T07:39:44+00:00
31January, 2023

Inclisiran’s Interesting Path to Treating LDL Cholesterol

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

When The Medicines Company licensed inclisiran, they envisioned a drug for the masses that would save the healthcare system money and be reasonably priced for patients. Despite the company having little experience in the oligonucleotide therapeutics field, it went all in on the drug, selling off its other products and ...

19January, 2023

Alnylam’s 20-Year Journey of Discovery

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Twenty years ago, a group of scientists intent on developing a new class of medicine using RNAi technology came together and formed Alnylam Pharmaceuticals, a name symbolizing their passion for discovery. The bright center star of Orion's belt, Alnilam, has long been used as a celestial navigator, guiding explorers in ...

4January, 2023

New CRISPR Technique May Be the Solution to Replacing Entire Genes

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Ever since it was discovered that CRISPR could be used for genome editing, scientists across the world have been working on creating safe, effective ways to use this incredible tool to cure many different human diseases. From the first CRISPR-Cas system that works as genetic scissors to base editing ...

12December, 2022

Using CRISPR to Personalize Cancer Immunotherapy Treatment

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

In 2020, there were an estimated 18.1 million cases of cancer worldwide (excluding non-melanoma skin cancer). Breast, lung, and colorectal cancer were the most common and together contributed to 35.4% of these cases. In the same year, 9.5 million cancer-related deaths were reported. According to the NIH, by 2040, it ...

22November, 2022

Will N-of-1 Drugs Play a Role in the Future of Medicine?

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Throughout the millennia, anyone who had anything beyond a simple illness could only do their best to ease the pain and petition whatever deities their culture believed in. Then, in the past few centuries, medicine and science have advanced to the point that many illnesses and diseases can be ...

9November, 2022

Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could change the treatment of genetic diseases. Now, their company’s drug that uses their proprietary technology has been granted orphan drug status by the U.S Food and Drug Administration (FDA). The drug, ABX1100, is designed ...

3November, 2022

Reflections following the 20th annual meeting on oligonucleotide therapeutics

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman Report, copyright 2022, and reprinted with permission. A Brief History of Oligonucleotide Therapeutics About 50 years ago, several scientists independently conceived of the idea of blocking gene expression with synthetic DNA or RNA “antisense” ...

23September, 2022

Eplontersen May Soon Provide Another Safe, Effective Treatment for People Diagnosed with ATTR

Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

People who have been diagnosed with hereditary transthyretin amyloidosis (ATTRv) may soon have the option of choosing another safe, effective therapy, one that significantly improves quality of life, according to patients who received it in the clinical trial. ATTRv is a progressive, debilitating, fatal disease in which amyloids ...

8September, 2022

The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond

Categories: Perspectives on Current Science|

More than 30 years ago, Dr. Stanley Crooke founded Ionis Pharmaceuticals — a biotech company that helped pioneer the now successful technology of antisense oligonucleotides (ASO) despite overwhelming challenges and widespread disbelief. After stepping down last year as the company's CEO, Crooke recently published a perspective of his journey ...

Reflections following the 20th annual meeting on oligonucleotide therapeutics

November 3rd, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman Report, copyright 2022, and reprinted with permission. A Brief History of Oligonucleotide Therapeutics About ...

Eplontersen May Soon Provide Another Safe, Effective Treatment for People Diagnosed with ATTR

September 23rd, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

People who have been diagnosed with hereditary transthyretin amyloidosis (ATTRv) may soon have the option of choosing another safe, effective therapy, one that significantly improves quality of life, according ...

The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond

September 8th, 2022|Categories: Perspectives on Current Science|

More than 30 years ago, Dr. Stanley Crooke founded Ionis Pharmaceuticals — a biotech company that helped pioneer the now successful technology of antisense oligonucleotides (ASO) despite overwhelming challenges ...

Get the Latest News!

  • Category

Go to Top